[Seroepidemiological survey of infection in patients with gynecological malignant tumors].

OBJECTIVE

To investigate the seroprevalence of infection in patients with gynecological malignant tumors, so as to provide the evidence for the control of infections in the patients with gynecological malignant tumors.

METHODS

A total of 327 patients with gynecological malignant tumors were recruited, and 200 women with normal healthy examinations were served as controls. The serum anti- IgG and IgM antibodies were detected by using ELISA, and the seroprevalence was compared between the patients and controls, and among various types of cancers.

RESULTS

The overall seroprevalence of was 26.91% (88/327) in the patients with gynecological malignant tumors, which was significantly higher than that (5.00%) in the healthy volunteers ( = 39.36, <0.01) . The prevalence of anti- IgG antibody in the cancer patients was significantly higher than that in the controls (26.30% vs. 5.00%; = 37.79, <0.01), while the prevalence of anti- IgM antibody in the cancer patients was not significantly different from that in the controls (0.92% . 0; corrected = 0.58, > 0.01) . The positive rates of anti- IgG antibody were 27.68%, 25.47% and 25.69% in ovarian cancer, cervical cancer, and breast cancer patients respectively, which were all significantly higher than those in the controls ( = 32.35, 27.32 and 28.00; all values<0.01); however, there was no significant difference among the various types of cancer patients in the positive rates of anti- IgG antibody ( = 0.17, > 0.05) . In addition, the positive rates of anti- IgM antibody were 1.79%, 0 and 0.92% in ovarian cancer, cervical cancer and breast cancer patients respectively, which was not significantly different from those in the controls (all values > 0.05).

CONCLUSIONS

The seroprevalence of infection is high in the patients with gynecological malignant tumors. It is suggested that the prevention and control of infection should be strengthened in these patients.